Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hansoh Pharma Licenses Hengrui’s SHR6508 for RMB 220 Million to Expand Renal Portfolio

Fineline Cube Dec 29, 2025
Company Deals

Luye Pharma Divests 25% Nanjing Luye Stake in RMB 1.1 Billion Complex Option Deal

Fineline Cube Dec 29, 2025
Company Deals

Transcenta Licenses HiCB Platform to EirGenix for Continuous Biomanufacturing

Fineline Cube Dec 29, 2025
Company Deals

TJ Biopharma Partners with Zhejiang Lab to Develop AI‑Driven Ultra‑Long‑Acting Growth Hormone

Fineline Cube Dec 29, 2025
Company Deals

HBM Holdings and Lannacheng Biotech Forge Strategic Alliance for Next‑Generation RDCs in Precision Oncology

Fineline Cube Dec 29, 2025
Policy / Regulatory

NMPA Releases 2025 Priority Approval Directory for Eight High-End Medical Device Categories

Fineline Cube Dec 29, 2025
Company Drug

Boan Biotech Ships First Batch of Boyoujing Aflibercept Biosimilar in China

Fineline Cube Dec 29, 2025
Company Drug

BDgene Doses First Patient with BD920 CRISPR Gene Therapy for HPV-16 HSIL

Fineline Cube Dec 29, 2025
Company Drug

HutchMed’s FRESCO-2 Study for Elunate in Colorectal Cancer Meets Primary Endpoint

Fineline Cube Aug 8, 2022

China-based Hutchison China Meditech (HutchMed; NASDAQ: HCM, HKG: 0013) announced that the pivotal global Phase...

Company Deals

Frontier Biotech Partners with Kindstar to Boost Anti-Infection Testing, Especially for HIV

Fineline Cube Aug 8, 2022

China-based Frontier Biotechnologies Inc. (SHA: 688221) has entered into a partnership with compatriot firm Kindstar...

Company Drug

Innovent Biologics Doses First Subject in IBI324 Phase I Study for DME

Fineline Cube Aug 8, 2022

China-based biotech Innovent Biologics Inc. (HKG: 1801) announced that the first subject has been dosed...

Company Drug

Immvira’s Oncolytic Virus MVR-C5252 Receives FDA Orphan Drug Designation for Glioma

Fineline Cube Aug 8, 2022

Shenzhen-based Immvira Co., Ltd, a biotech company focused on oncolytic viruses, announced that it has...

Company Legal / IP R&D

Transcenta Appoints Dr. Caroline Germa as Global Drug Development Chief

Fineline Cube Aug 8, 2022

China-based biotech Transcenta Holdings Ltd (HKG: 6628) announced the appointment of Dr. Caroline Germa as...

Hospital Policy / Regulatory

NHC Issues Notification on Medication Safety Management and Rational Drug Use

Fineline Cube Aug 8, 2022

The National Healthcare Commission (NHC) has released a notification focusing on medication safety management and...

Company Deals

Ningbo Health Gene Raises Hundreds of Millions in Series C Financing

Fineline Cube Aug 8, 2022

Ningbo Health Gene Technologies Co., Ltd, a China-based medical testing solution provider, has reportedly raised...

Company Medical Device

Intuitive Surgical-Fosun JV Breaks Ground on Shanghai Medical Robot Base

Fineline Cube Aug 8, 2022

Intuitive Surgical-Fosun Medical Technology (Shanghai) Co., Ltd, a joint venture (JV) between China-based Shanghai Fosun...

Company

Bayer AG’s Q2 2022 Results Show Global Sales Growth Amid China VBP Pressures

Fineline Cube Aug 8, 2022

Germany-based pharmaceutical giant Bayer AG (VIE: BAYN) released its Q2 2022 financial report, revealing a...

Company Deals

Intellective Biologics Raises Over RMB500m in Series C Financing Round

Fineline Cube Aug 5, 2022

China-based macromolecule-focused Contract Development and Manufacturing Organization (CDMO) Intellective Biologics (Suzhou) Co., Ltd has reportedly...

Company Deals

MicuRx Pharmaceuticals Completes RMB1.06B IPO for Antibacterial Drug Development

Fineline Cube Aug 5, 2022

Shanghai-based antibacterial drug developer MicuRx Pharmaceuticals has officially made an initial public offering (IPO) of...

Company Deals

invoX Pharma Extends Tender Offer for F-star Therapeutics to September 19

Fineline Cube Aug 5, 2022

invoX Pharma Ltd, a UK-based subsidiary of China’s Sino Biopharmaceutical Ltd (HKG: 1177), announced that...

Company Drug

Merck Launches Prevymis, a Non-Nucleoside CMV Inhibitor, in China

Fineline Cube Aug 5, 2022

US pharmaceutical giant Merck Sharp & Dohme (MSD, NYSE: MRK) announced the commercial launch of...

Company

BeiGene’s Q2 2022 Revenues Surge 120%, Brukinsa Sales Triple

Fineline Cube Aug 5, 2022

BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) reported its financial results for Q2 2022, recording...

Company Deals

Innovent Biologics and Sanofi Announce License Deal for Drug Development in China

Fineline Cube Aug 5, 2022

China-based biotech firm Innovent Biologics Inc. (HKG: 1801) and France’s Sanofi SA (NASDAQ: SNY) have...

Company

Eli Lilly Reports First Quarterly Revenue Dip in Two Years, China Sales Plunge

Fineline Cube Aug 5, 2022

US-based Eli Lilly & Co. (NYSE: LLY) released its Q2 2022 financial report, revealing a...

Company

Novo Nordisk’s H1 2022 Results Show Strong Global Sales Growth, China Sales Dip

Fineline Cube Aug 5, 2022

Denmark-based Novo Nordisk (NYSE: NVO) released its H1 2022 financial results, reporting a 14% year-on-year...

Company Deals

Shanghai Pharmaceuticals Partners with HKSTP and Shanghai Biomedicine Fund on R&D Collaboration

Fineline Cube Aug 5, 2022

Shanghai Pharmaceuticals (HKG: 2607, SHA: 601607), a leading Chinese pharmaceutical company, has entered into a...

Company Drug

Zhongsheng Pharmaceutical Completes Phase I Study of RAY1216 for COVID-19 Treatment

Fineline Cube Aug 5, 2022

China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) announced the completion of subject enrollment and...

Company Drug

CSPC Pharmaceutical’s rhTNK-tPA Meets Primary Endpoint in Stroke Study

Fineline Cube Aug 5, 2022

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that the Phase III clinical study for...

Posts pagination

1 … 576 577 578 … 602

Recent updates

  • Hansoh Pharma Licenses Hengrui’s SHR6508 for RMB 220 Million to Expand Renal Portfolio
  • Luye Pharma Divests 25% Nanjing Luye Stake in RMB 1.1 Billion Complex Option Deal
  • Transcenta Licenses HiCB Platform to EirGenix for Continuous Biomanufacturing
  • Boan Biotech Ships First Batch of Boyoujing Aflibercept Biosimilar in China
  • BDgene Doses First Patient with BD920 CRISPR Gene Therapy for HPV-16 HSIL
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Hansoh Pharma Licenses Hengrui’s SHR6508 for RMB 220 Million to Expand Renal Portfolio

Company Deals

Luye Pharma Divests 25% Nanjing Luye Stake in RMB 1.1 Billion Complex Option Deal

Company Deals

Transcenta Licenses HiCB Platform to EirGenix for Continuous Biomanufacturing

Company Drug

Boan Biotech Ships First Batch of Boyoujing Aflibercept Biosimilar in China

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.